We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Johnson & Johnson's Johnson & Johnson Development Corp. purchased $32.8mm (DKK207.5mm) new Bavarian Nordic AS stock in a private placement of 512,102 shares priced at $64.18. As a result, JJDC now holds 1,844,086 shares in Bavarian Nordic corresponding to 5.77% of the share capital and voting rights. The financing is part of a concurrent deal between Bavarian Nordic and J&J's Janssen Pharmaceuticals Inc. subsidiary in which Janssen received exclusive global rights to use MVA-BN technology to develop vaccines for hepatitis B virus and HIV.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Vaccines
Drug Delivery
Macromolecule
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Financing
Private Investment in Public Equity
Private Placement
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?